Victory Capital Management
ORIC icon

Victory Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Victory Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.26M Sell
393,070
-12,210
-3% -$111K ﹤0.01% 1417
2026
Q1 		$5.13M Buy
405,280
+72,520
+22% +$823K ﹤0.01% 1320
2025
Q4 		$2.72M Buy
332,760
+200,540
+152% +$2.31M ﹤0.01% 1505
2025
Q3 		$1.59M Sell
132,220
-410
-0.3% -$4.31K ﹤0.01% 1670
2025
Q2 		$1.35M Sell
132,630
-17,630
-12% -$118K ﹤0.01% 1715
2025
Q1 		$838K Buy
150,260
+52,760
+54% +$461K ﹤0.01% 1879
2024
Q4 		$787K Sell
97,500
-2,250
-2% -$20.6K ﹤0.01% 1902
2024
Q3 		$1.02M Buy
99,750
+3,900
+4% +$38.6K ﹤0.01% 1768
2024
Q2 		$678K Buy
95,850
+7,310
+8% +$65.4K ﹤0.01% 1881
2024
Q1 		$1.22M Sell
88,540
-37,490
-30% -$445K ﹤0.01% 1646
2023
Q4 		$1.16M Buy
126,030
+1,180
+0.9% +$8.53K ﹤0.01% 1646
2023
Q3 		$755K Sell
124,850
-12,180
-9% -$99.8K ﹤0.01% 1804
2023
Q2 		$1.06M Sell
137,030
-21,400
-14% -$122K ﹤0.01% 1645
2023
Q1 		$903K Buy
+158,430
New +$828K ﹤0.01% 1753
2022
Q4 		– Sell
-47,479
Closed -$152K – 2679
2022
Q3 		$152K Sell
47,479
-479
-1% -$1.92K ﹤0.01% 2400
2022
Q2 		$215K Buy
47,958
+39
+0.1% +$156 ﹤0.01% 2328
2022
Q1 		$159K Sell
47,919
-1,757,798
-97% -$15.8M ﹤0.01% 2444
2021
Q4 		$26.5M Buy
1,805,717
+259,394
+17% +$4.04M 0.02% 810
2021
Q3 		$32.3M Buy
1,546,323
+241,963
+19% +$4.9M 0.03% 703
2021
Q2 		$23.1M Buy
1,304,360
+198,986
+18% +$4.36M 0.02% 850
2021
Q1 		$27.1M Buy
1,105,374
+5,081
+0.5% +$161K 0.03% 792
2020
Q4 		$37.2M Buy
1,100,293
+203,159
+23% +$5.83M 0.04% 626
2020
Q3 		$22.4M Buy
897,134
+329,014
+58% +$7.83M 0.03% 742
2020
Q2 		$19.2M Buy
+568,120
New +$18.1M 0.03% 802

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Victory Capital Management's ORIC Position: Q2 2026 in Review

Victory Capital Management reduced its Oric Pharmaceuticals (ORIC) stake by 3% in Q2 2026, selling an estimated $111K and leaving 393,070 shares worth $4.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1417.

Victory Capital Management first reported a position in ORIC in Q2 2020 and has held it in 24 quarters since. The position peaked at $37.2M in Q4 2020. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Victory Capital Management held 393,070 shares of Oric Pharmaceuticals worth $4.26M as of Q2 2026.
  • Victory Capital Management sold 12,210 Oric Pharmaceuticals shares in Q2 2026, an estimated $111K.
  • Oric Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1417 holding.
  • Victory Capital Management first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Victory Capital Management's Oric Pharmaceuticals position peaked at $37.2M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.